Stock Taper 
Mineralys Therapeutics, Inc., founded in 2019 in Radnor, PA, is a clinical-stage biopharmaceutical company developing lorundrostat, an oral, selective aldosterone synthase inhibitor for resistant hypertension and cardiovascular diseases.
Lorundrostat, a highly selective oral aldosterone synthase inhibitor in late-stage development by Mineralys Therapeutics, aims to treat resistant hypertension, chronic kidney disease, and sleep apnea, with positive Phase 3 trial results.
In late 2025, Mineralys Therapeutics announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead drug candidate, lorundrostat, for the treatment of uncontrolled and resistant hypertension. This filing was the culmination of a successful clinical program in 2025, including three positive pivotal trials that demonstrated lorundrostat's efficacy and safety, positioning it as a potentially best-in-class treatment.
In 2025, Mineralys Therapeutics executed two significant underwritten public offerings, raising a combined total of approximately $488.7 million. This series of capital infusions was a deliberate strategy to fund the extensive clinical development, manufacturing, and pre-commercialization activities for its lead product candidate, lorundrostat, following positive pivotal trial results.
What happened Mineralys Therapeutics, Inc. (NASDAQ: MLYS) said Chief Executive Officer and director Jon Congleton sold 75,000 shares on 2026-09-30. The Form 4 says the shares changed hands at a weighted-average $25.46 each in multiple transactions. Those sales ranged from $25.00 to $25.82 a share. The transaction totaled about $1.91 million. Afterward, Congleton still held
RADNOR, Pa., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that new data from the Launch-HTN trial of lorundrostat will be presented at the American Society of Nephrology Kidney Week 2026, taking place October 21-25 in Denver, Colorado.
RADNOR, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that five abstracts will be presented at the American Heart Association (AHA) Hypertension Scientific Sessions 2026, taking place October 7-11 in Arlington, VA.
Overall rating: C
| PEER | PRICE | |
|---|---|---|
 SRRK | $42.38 | COMPARE |
 TVTX | $52.58 | COMPARE |
 ADPT | $27.44 | COMPARE |
 IDYA | $36.71 | COMPARE |
 ZLAB | $25.73 | COMPARE |
 BEAM | $25.14 | COMPARE |
 RXRX | $4.54 | COMPARE |
 VERA | $29.18 | COMPARE |
